Worth More Dead Than Alive?
Orexigen Mulls Next Steps After FDA's Contrave Surprise
By Tom Wall
Wednesday, February 2, 2011
"Premature to speculate" and "need more details" were default answers for Orexigen Therapeutics Inc. CEO Michael Narachi as he attempted to respond to questions during a conference call Tuesday about what's next for the San Diego-based company's new drug application (NDA) for Contrave (naltrexone HCl/bupropion HCl) extended-release tablets for the treatment of obesity.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.